Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Helios
Tokyo, Tokyo-to, Japan
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Helios has advanced several iPSC-derived allogeneic cell therapies to clinical trials, including a Phase 2/3 program in ischemic stroke and ongoing development in ARDS and cancer. Recent acquisition of MultiStem assets allows Helios to expand into multipotent adult progenitor cell therapeutics.
- Therapeutic areas
- OncologyOphthalmologyCardiovascularPulmonology
- Modalities
- Cell therapyGene therapyInduced pluripotent stem cell derived therapyAllogeneic cell therapy
- Industry
- Biotech
02
Partnerships
iPS Academia JapanRIKENDaiichi Sankyo (now Sumitomo Pharma)Alfresa CorporationAND medical group
Beyond the preview
Go deeper on Helios.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helios.